

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/937,519	1	03/05/2002	Guido Krupp	P-UX 4977	9641
41552	7590	12/05/2005		EXAMINER	
	MCDERMOTT, WILL & EMERY 4370 LA JOLLA VILLAGE DRIVE, SUITE 700 SAN DIEGO, CA 92122		STRZELECKA, TERESA E		
				ART UNIT	PAPER NUMBER
	•			1637	

DATE MAILED: 12/05/2005

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

APPLICATION NO.J CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION		ATTORNEY DOCKET NO.
,				EXAMINER
			ART UNIT	PAPER
				30112005

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

- 1. The reply filed on September 12, 2005 is not fully responsive to the prior Office Action because of the following omission(s) or matter(s): pages 4 and 5 of the Response, which contain amendments to the specification concerning sequences, do not contain SEQ ID NOs in lines 5, 6, 14 and 17 of page 4 and on the last line of page 5. See 37 CFR 1.111. Since the above-mentioned reply appears to be bona fide, applicant is given ONE (1) MONTH or THIRTY (30) DAYS from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).
- 2. Enclosed is the bona fide letter, Notice to Comply and copy of the "Raw Sequence Listing Error Report" regarding sequence listing submitted by Applicants on September 12, 2005.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Teresa E. Strzelecka whose telephone number is (571) 272-0789. The examiner can normally be reached on M-F (8:30-5:30). If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached on (571) 272-0782. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

TERESA STRZELECKA
PATENT EXAMINER
Teresa Strubeclia
11/30/05

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, DC 2023I
WWW.USDIO.GOV

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	········	ATTORNEY DOCKET NO.
				EXAMINER
	·			EAMINER
			ART UNIT	PAPER
				30112005

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents

The communication filed September 12, 2005 is not fully responsive to the Office communication mailed March 11, 2005 for the reason(s) set forth on the attached Notice To Comply With The Sequence Rules or CRF Diskette Problem Report. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

Since the reply appears to be <u>bona fide</u> attempt to comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825), applicant is given a TIME PERIOD of **ONE** (1) **MONTH** from the mailing date of this communication within which to correct the deficiency so as to comply with the sequence rules (37 CFR 1.821 - 1.825) in order to avoid abandonment of the application under 37 CFR 1.821(g). EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).

Any inquiry concerning this communication should be directed to Examiner Teresa Strzelecka, Art Unit 1637, whose telephone number is (571)-272-0789.

Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center receptionist whose telephone number is (703) 308-0196.

TERESA STRZELECKA
PATENT EXAMINER

Teresa Strelectia 11/30/05

	Application No.	Applicant(s)		
Notice to Comply	09/937,519	KRUPP, GUIDO		
House to Comply	Examiner	Art Unit		
	Teresa E. Strzelecka	1637		
NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES				
Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).				
The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):				
1. This application clearly fails to comply with the red directed to the final rulemaking notice published at 5 the effective filing date is on or after July 1, 1998, se 1998) and 1211 OG 82 (June 23, 1998).	5 FR 18230 (May 1, 1990), and 1	114 OG 29 (May 15, 1990).	. If	
2. This application does not contain, as a separate p required by 37 C.F.R. 1.821(c).	art of the disclosure on paper cop	y, a "Sequence Listing" as		
3. A copy of the "Sequence Listing" in computer reaction 37 C.F.R. 1.821(e).	lable form has not been submitted	d as required by		
4. A copy of the "Sequence Listing" in computer rea computer readable form does not comply with the re attached copy of the marked -up "Raw Sequence List	quirements of 37 C.F.R. 1.822 an			
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).				
☐ 6. The paper copy of the "Sequence Listing" is not the as required by 37 C.F.R. 1.821(e).	e same as the computer readable	from of the "Sequence List	ting"	
7. Other:				
Applicant Must Provide: ☑ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".	•		
\boxtimes An initial or substitute paper copy of the "Sequence I specification.	Listing", as well as an amendmen	directing its entry into the		
A statement that the content of the paper and comp no new matter, as required by 37 C.F.R. 1.821(e) or 1.82			ıclude	
For questions regarding compliance to these re	equirements, please contact	:		
For Rules Interpretation, call (703) 308-4216 For CRF Submission Help, call (703) 308-4212 PatentIn Software Program Support				
Technical Assistance To Purchase Patentln Software				
PLEASE RETURN A COPY OF THIS NOTICE	WITH YOUR REPLY			

STIC Biotechnology Systems Branch

RAW SEQUENCE LISTING ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number:	09/937.519
Source:	176/16
Date Processed by STIC:	9/19/05

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.
PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,

2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION AND PATENTIN SOFTWARE QUESTIONS, PLEASE CONTACT MARK SPENCER, TELEPHONE: 571-272-2510; FAX: 571-273-0221

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE <u>CHECKER VERSION 4.2.2 PROGRAM</u>, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

http://www.uspto.gov/web/offices/pac/checker/chkrnote.htm

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail. Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

I. EFS-Bio (<http: th="" www.us<=""><th>pto.gov/ebc</th><th><u>/efs/downloads/documents.htm></u> ,</th><th>EFS Submission</th></http:>	pto.gov/ebc	<u>/efs/downloads/documents.htm></u> ,	EFS Submission
User Manual - ePAVE)		•	

2. U.S. Postal Service: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

3. Hand Carry, Federal Express, United Parcel Service, or other delivery service (EFFECTIVE 01/14/05):
U.S. Patent and Trademark Office, Mail Stop Sequence, Customer Window, Randolph Building. 401 Dulany-Street

Alexandria, VA · 223·14

Revised 01/24/05

Raw Sequence Listing Error Summary

ERROR DETECTED	SUGGESTED CORRECTION SERIAL NUMBER: 09/937579
ATTN: NEW RULES CASES	S: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE
	The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3; this will prevent "wrapping."
2Invalid Line Lengtl	The rules require that a line not exceed 72 characters in length. This includes white spaces.
3Misaligned Amino Numbering	The numbering under each 5 th amino acid is misaligned. Do not use tab codes between numbers; use space characters, instead.
4Non-ASCII	The submitted file was not saved in ASCII(DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text.
5Variable Length	Sequence(s) contain n's or Xaa's representing more than one residue. Per Sequence Rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the <20>-<223> section that some may be missing.
6PatentIn 2.0 "bug"	A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequences(s) Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences.
7Skipped Sequences (OLD RULES)	Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence: (2) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown) (i) SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading) (xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: (insert SEQ ID NO where "X" is shown) This sequence is intentionally skipped
	Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to include the skipped sequences.
8Skipped Sequences (NEW RULES)	Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence. <10> sequence id number <400> sequence id number 000
9Use of n's or Xaa's (NEW RULES)	Use of n's and/or Xaa's have been detected in the Sequence Listing. Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present. In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.
10Invalid <213> Response	Per 1.823 of Sequence Rules, the only valid <213> responses are: Unknown, Artificial Sequence, or scientific name (Genus/species). <220>-<223> section is required when <213> response is Unknown or is Artificial Sequence
11Use of <220>	Sequence(s) missing the <220> "Feature" and associated numeric identifiers and responses. Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or "Unknown." Please explain source of genetic material in <220> to <223> section. (See "Federal Register," 06/01/1998, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of Sequence Rules)
oug	Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.
13 Misuse of n/Xaa	"n" can only represent a single nucleotide; "Xaa" can only represent a single amino acid



IFW16

RAW SEQUENCE LISTING DATE: 09/19/2005 PATENT APPLICATION: US/09/937,519 TIME: 10:23:32

Input Set : A:\66741-013; seq. listing
Output Set: N:\CRF4\09192005\1937519.raw

```
2 <110> APPLICANT: Krupp, Guido
      4 <120> TITLE OF INVENTION: Detection of nucleic acid amplified products
      6 <130> FILE REFERENCE: 66741-013
      8 <140> CURRENT APPLICATION NUMBER: 09/937,519
      9 <141> CURRENT FILING DATE: 2002-03-05
     11 <150> PRIOR APPLICATION NUMBER: PCT/EP99/07127
    .12 <151> PRIOR FILING DATE: 1999-09-27
     14 <150> PRIOR APPLICATION NUMBER: DE 199 15 141.5
     15 <151> PRIOR FILING DATE: 1999-03-26
     17 <160> NUMBER OF SEQ ID NOS: 202
                                                                     Does Not Comply
     19 <170> SOFTWARE: PatentIn Ver. 2.1
                                                                     ected Diskette Neede
     21 <210> SEQ ID NO: 1
     22 <211> LENGTH: 4
     23 <212> TYPE: DNA
     24 <213> ORGANISM: artificial sequence
     28 (225) FEATURE: delete Atra (2207 (global sum)
29 (223) OTHER INFORMATION: DESCRIPTION
     29 <223> OTHER INFORMATION: Description of the molecule of DNA/RNA combination:
     30
              artificial DNA sequence
     32 <220> FEATURE:
     33 <223> OTHER INFORMATION: Description of the artificial sequence: (artificial
            ( RNA sequence
     36 <400> SEQUENCE+
     37 gaaa
     40 <210> SEQ ID NO: 2
     41 <211> LENGTH: 7
     42 <212> TYPE: DNA
     43 <213> ORGANISM: artificial sequence
     45 <220> FEATURE:
     47 (220 > FEATURE:) dela
     48 <223> OTHER INFORMATION: Description of the artificial sequence
           RNA sequence
     49
                    7 Ms Leed explanation (see p.7)
    51 <400>
             SEQUENCE: 2
W--> 52 cuganda-
     55 <210> SEQ ID NO: 3
     56 <211> LENGTH: 14
     57 <212> TYPE: DNA
    58 <213> ORGANISM: artificial sequence
    60 <220> FRATURE:
    62 C220> FRATURE:
    63 <223> OTHER INFORMATION: Description of the artificial sequence artificial
            DNA sequence
    66 <400> SEQUENCE: 3
```

DATE: 09/19/2005

TIME: 10:23:32

```
Input Set : A:\66741-013; seq. listing
                                               Output Set: N:\CRF4\09192005\1937519.raw
           67 tccgagccgg wcgr
                                                                                                                                                                   14
           70 <210> SEQ ID NO: 4
           71 <211> LENGTH: 16
           72 <212> TYPE: DNA
           73 <213> ORGANISM: artificial sequence
           75 <220> FEATURE:
           77 <220> FEATURE.
           78 <223> OTHER THEORMATION: Description of the artificial sequence: artificial
                          C DNA sequence
           81 <400> SEQUENCE: 4
           82 rggctagcha caacga
                                                                                                                                                                   16
           85° <210> SEQ ID NO: 5
           86 <211> LENGTH: 13
                                                                                                            also combered ONA/PNA
           87 <212> TYPE: DNA
           88 <213> ORGANISM: artificial sequence
           90 <220> FEATURE:
           92 <220> FEATURE:
           93 <223> OTHER INFORMATION: Description of the artificial sequence: artificial
                           RNA sequence
           96 <400> SEQUENCE: 5
           97 ggaaucgaaa cgc
                                                                                                                                                                   13
           100 <210> SEQ ID NO: 6
           101 <211> LENGTH: 32
           102 <212> TYPE: DNA
           103 <213> ORGANISM: artificial sequence
           105 <220> FEATURE:
           106 <221> NAME/KEY: modified base
           107 <222> LOCATION: (24). ((25)) (24)
           108 <223> OTHER INFORMATION: modified nucleotide at position 24:
           109
                                 Pyridin-4-one (cf. Burgin et al., 1996)
           111 <220> FEATURE:
           112 <223 OTHER INFORMATION: Description of the artificial sequence: artificial
                                RNA/DNA sequence
           113
           115 <220> FEATURE:
           116 <221> NAME/KEY: modified base
                                                                                                                                                                                moternal
           117 <222> LOCATION: (27)..((28)) (27)
           118 <223> OTHER INFORMATION: modified nucleotide at position 27:
                                Pyridin-4-one (cf. Burgin et al., 1996)
           121 <400> SEQUENCE: 6
                                                                                                     + why walt
W--> 122 gcgtctagcg gaaacgctac tgangagatt cc
          125 <210> SEQ ID NO: 7
          126 <211> LENGTH: 22
          127 <212> TYPE: DNA
         128 <213> ORGANISM: artificial sequence
130 <220> FEATURE:
132 <220> FRATURE:

The product of th
          132 <220> FEATURE
          133 <223> OTHER INFORMATION: Description of the artificial sequence; artificial
          134
                     RNA sequence
                                                                                                                   usufficit
          136 <400> SEQUENCE: 7
```

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/937,519

DATE: 09/19/2005

TIME: 10:23:32

Input Set : A:\66741-013; seq. listing Output Set: N:\CRF4\09192005\1937519.raw 137 gcagcuaugg aaayguuaaa ag 22 140 <210> SEQ ID NO: 8 141 <211> LENGTH: 40 142 <212> TYPE: DNA 143 <213> ORGANISM: artificial sequence 145 <220> FEATURE: 147 220> FEATURE 148 <223> OTHER INFORMATION: Description of the artificial sequence: artificial RNA/DNA sequence also, quie source of Artificial Seguence on another (2237) line 151 <220> FEATURE: 152 <221> NAME/KEY: modified_base 153 <222> LOCATION: (29). (30) (29) 154 <223> OTHER INFORMATION: modified nucleotide at position 29: 155 Pyridin-4-one (cf. Burgin et al., 1996) 157 <400> SEQUENCE: 8 W--> 158 ttttaacruc tagcggaaac gctactgang acatagctgc 40 161 <210> SEQ ID NO: 9 162 <211> LENGTH: 54 163 <212> TYPE: DNA 164 <213> ORGANISM: artificial sequence 166 <220> FEATURE: 168 <220> FEATURE: 169 <223> OTHER INFORMATION: Description of the artificial sequence: primer 171 <400> SEQUENCE: 9 172 aattctaata cgactcacta tagggtgcta tgtcacttcc ccttggttct ctca 175 <210> SEQ ID NO: 10 176 <211> LENGTH: 46 177 <212> TYPE: DNA 178 <213> ORGANISM: artificial sequence 180 <220> FEATURE: 182 <220> FEATURE: 183 <223> OTHER INFORMATION: Description of the artificial sequence: primer 185 <400> SEQUENCE: 10 186 gaatctcatc agtagcgagt ggggggacat caagcagcca tgcaaa 46 189 <210> SEQ ID NO: 11 190 <211> LENGTH: 28 191 <212> TYPE: DNA

192 <213> ORGANISM: artificial sequence

194 <220> FEATURE:

196 <220> FEATURE:

197 <223> OTHER INFORMATION: Description of the artificial sequence: artificial manifement RNA sequence 200 <400> SEQUENCE: 11 201 tgaaucgaaa cgcgaaagcg ucuagcgu 28 204 <210> SEQ ID NO: 12 205 <211> LENGTH: 46 206 <212> TYPE: DNA 207 <213> ORGANISM: artificial sequence 209 <220> FEATURE:

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/937,519

RAW SEQUENCE LISTING DATE: 09/19/2005
PATENT APPLICATION: US/09/937,519
TIME: 10:23:32

Input Set : A:\66741-013; seq. listing
Output Set: N:\CRF4\09192005\I937519.raw

```
211 (220) FEATURES
 212 <223> OTHER INFORMATION: Description of the artificial sequence: primer
 214 <400> SEQUENCE: 12
 215 gaatctcatc agtagcgagt ggggggacat caagcagcca tgcaaa
 218 <210> SEQ ID NO: 13
 219 <211> LENGTH: 15
220 <212> TYPE: DNA
220 <212> TYPE: DNA

221 <213> ORGANISM: artificial sequence

223 <220> FEATURE:

225 <220> FEATURE:

226 <223> OTHER INFORMATION: Description of the artificial sequence artificial brilliant

227 RNA sequence

229 <400> SEQUENCE: 13
230 tacguagucc gugcu
                                                                                15
233 <210> SEQ ID NO: 14
234 <211> LENGTH: 13
235 <212> TYPE: DNA
236 <213> ORGANISM: artificial sequence
238 <220> FEATURE:
240 <220> FEATURE:
241 <223> OTHER INFORMATION: Description of the artificial sequence: primer
243 <400> SEQUENCE: 14
244 gcgtttcgat tcc
                                                                                13
247 <210> SEQ ID NO: 15
248 <211> LENGTH: 142
249 <212> TYPE: DNA
250 <213> ORGANISM: Human immunodeficiency virus type 1
252 220> FEATURE dela - La 22217, 22227, or 22237, so 22207 is hot helded
254 <400> SEQUENCE: 15
255 agtgggggga catcaagcag ctatgcaaac gttaaaagat actatcaatg aggaagctgc 60
256 agaatgggac agggtacatc cagtacatgc agggcctatt ccaccaggcc agatgagaga 120
257 accaagggga agtgacatag ca
260 <210> SEQ ID NO: 16
261 <211> LENGTH: 24
262 <212> TYPE: DNA
263 <213> ORGANISM: artificial sequence
265 <220> FEATURE:
267 2205 FEATURE:
268 <223> OTHER INFORMATION: Description of the artificial sequence: artificial
         DNA sequence
271 <400> SEQUENCE: 16
272 agcagctatg gaaaygttaa aaga
                                                                                24
275 <210> SEQ ID NO: 17
276 <211> LENGTH: 54
277 <212> TYPE: DNA
278 <213> ORGANISM: artificial sequence
280 <220> FEATURE:
282 (220) FEATURE?
283 <223> OTHER INFORMATION: Description of the artificial sequence: primer
```

RAW SEQUENCE LISTING DATE: 09/19/2005 PATENT APPLICATION: US/09/937,519 TIME: 10:23:32

Input Set : A:\66741-013; seq. listing Output Set: N:\CRF4\09192005\1937519.raw

```
285 <400> SEQUENCE: 17
286 aattctaata cgactcacta tagggagtgg ggggacatca agcagctatg gaaa
289 <210> SEQ ID NO: 18
                                                also Alw is
a combined ONAJRNA insufficiely
290 <211> LENGTH: 42
291 <212> TYPE: DNA
292 <213> ORGANISM: artificial sequence
294 <220> FEATURE:
296 <220> FEATURE:
297 <223> OTHER INFORMATION: Description of the artificial sequence: artificial
        (RNA sequence)
300 <400> SEQUENCE: 18
301 gggagtgggg ggacatcaag cagctatgga aayguuaaaa ga
                                                                              42
304 <210> SEQ ID NO: 19
305 <211> LENGTH: 24
306 <212> TYPE: DNA
307 <213> ORGANISM: Escherichia coli
309 (220) FEATURE: delete
311 <400> SEQUENCE: 19
312 taatgtctgg gaaactgcct gatg
                                                                              24
315 <210> SEQ ID NO: 20
316 <211> LENGTH: 24
317 <212> TYPE: DNA
318 <213 ORGANISM: Escherichia coli
320 <220> PEATURE:
322 <400> SEQUENCE: 20
323 ataactactg gaaacggtag ctaa
                                                                             24
326 <210> SEQ ID NO: 21
327 <211> LENGTH: 24
328 <212> TYPE: DNA
329 <213> ORGANISM: Escherichia coli
331 <220> PEATURE:
333 <400> SEQUENCE: 21
334 agtcagatgt gaaatccccg ggct
                                                                             24
337 <210> SEQ ID NO: 22
338 <211> LENGTH: 24
339 <212> TYPE: DNA
340 <213 ORGANISM: Escherichia coli
342 <220 FEATURE:
344 <400> SEQUENCE: 22
345 gtgtagcggt gaaatgcgta gaga
                                                                             24
348 <210> SEQ ID NO: 23
349 <211> LENGTH: 24
350 <212> TYPE: DNA
351 <213> ORGANISM: Escherichia coli
353 <220> FEATURE:
355 <400> SEQUENCE: 23
356 gctcaggtgc gaaagcgtgg ggag
                                                                             24
359 <210> SEQ ID NO: 24
360 <211> LENGTH: 24
```

file://C:\CRF4\Outhold\VsrI937519.htm see p. 6 for MORE even 9/19/

<210> 57 <211> 24 <212> DNA

<213> Vibrio parahaemolyticus

<220>

<400> 57

"h' helde exploration (see p.7)

same lun en Segr. 170-171, 188, 195

VARIABLE LOCATION SUMMARY

PATENT APPLICATION: US/09/937,519

DATE: 09/19/2005 TIME: 10:23:33

Input Set : A:\66741-013; seq. listing
Output Set: N:\CRF4\09192005\1937519.raw

these sequence lack ""

Use of n's or Xaa's (NEW RULES):

Use of n's and/or Xaa's have been detected in the Sequence Listing.
Use of <220> to <223> is MANDATORY if n's or Xaa's are present.
in <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.

Seq#:2; N Pos. 5 Seq#:6; N Pos. 24 // Seq#:8; N Pos. 29,

Seq#:57; N Pos. 1

Seq#:170; N Pos. 18 Seq#:171; N Pos. 19

Seq#:171; N POS. 19 Seq#:188; N Pos. 24

Seq#:195; N Pos. 24

file://C:\CRF4\Outhold\VsrI937519.htm

VERIFICATION SUMMARY PATENT APPLICATION: US/09/937,519 DATE: 09/19/2005 TIME: 10:23:33

Input Set : A:\66741-013; seq. listing
Output Set: N:\CRF4\09192005\1937519.raw

```
L:52 M:258 W: Mandatory Feature missing, <221> Tag not found for SEQ ID#:2
L:52 M:258 W: Mandatory Feature missing, <222> Tag not found for SEQ ID#:2
L:52 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2 after pos.:0
L:122 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6 after pos.:0
L:158 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:8 after pos.:0
L:730 M:258 W: Mandatory Feature missing, <221> Tag not found for SEQ ID#:57
L:730 M:258 W: Mandatory Feature missing, <222> Tag not found for SEQ ID#:57 L:730 M:258 W: Mandatory Feature missing, <223> Tag not found for SEQ ID#:57
L:730 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:57 after pos.:0
L:1973 M:258 W: Mandatory Feature missing, <221> Tag not found for SEQ ID#:170
L:1973 M:258 W: Mandatory Feature missing, <222> Tag not found for SEQ ID#:170
L:1973 M:258 W: Mandatory Feature missing, <223> Tag not found for SEQ ID#:170
L:1973 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:170 after pos.:0
L:1984 M:258 W: Mandatory Feature missing, <221> Tag not found for SEQ ID#:171
L:1984 M:258 W: Mandatory Feature missing, <222> Tag not found for SEQ ID#:171
L:1984 M:258 W: Mandatory Feature missing, <223> Tag not found for SEQ ID#:171
L:1984 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:171 after pos.:0
L:2171 M:258 W: Mandatory Feature missing, <221> Tag not found for SEQ ID#:188
L:2171 M:258 W: Mandatory Feature missing, <222> Tag not found for SEQ ID#:188
L:2171 M:258 W: Mandatory Feature missing, <223> Tag not found for SEQ ID#:188
L:2171 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:188 after pos.:0
L:2248 M:258 W: Mandatory Feature missing, <221> Tag not found for SEQ ID#:195
L:2248 M:258 W: Mandatory Feature missing, <222> Tag not found for SEQ ID#:195
L:2248 M:258 W: Mandatory Feature missing, <223> Tag not found for SEQ ID#:195
L:2248 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:195 after pos.:0
```